Pacific Marine Biotech (PMB) is a United States-based biotech company founded in December 2021 by Samuel Grant and Alan Temkin. Their team’s mission is to provide a safe and natural treatment solution for Glioblastoma, GBM and Gliomas that restores quality of life by securing future Therapeutic Goods of Australia (TGA) and U.S. Food and Drug Administration approval for the investigational drug Immune12.
PMB's immediate objective is to recruit patients for the Australia Phase II Efficiency Trial who can potentially benefit from the trial. Additionally, they want to create partnerships with leading healthcare institutions in the US for the purpose of conducting clinical trials on Immune12. They envision a future in which they can positively change the way cancer is treated, rewriting the narrative for thousands of cancer patients every year and for the betterment of communities around the world.
We have secured a phase 2 clinical trial in Australia, click the button below to fill out the trial interest form.
If any patients, caregivers, or healthcare providers who are based in Australia, would like more information or to pre-qualify for this clinical trial should fill out our Interest Form or contact our EBCI Clinical Research Coordinator and Patient Navigator, Shreya Prakash, at Shreya@EndBrainCancer.org or at 425-436-8688.
A Phase 2 clinical trial of Immune12 is currently enrolling patients with glioblastoma brain cancer to support marketing authorization in Australia, with study locations in New South Wales and Queensland (registered with the Australian New Zealand Clinical Trials Registry, ANZCTR). The trial is led by Chief Principal Investigator Dr. Janet Schloss, PhD, ND, and plans to enroll approximately 60 participants. This study will evaluate how feasible the treatment is for patients, including how well participants are able to stay in the study and follow the treatment plan. Researchers will also study certain biomarkers in the blood, including those related to the kynurenine pathway, which may help scientists better understand how the body responds to treatment. In addition, the trial will assess patients’ quality of life during treatment. Doctors will use MRI scans throughout the study to monitor how tumors respond to treatment using established brain tumor evaluation guidelines called Response Assessment in Neuro-Oncology (RANO). Tumor responses may be categorized as complete response, partial response, stable disease, or disease progression. Learn more about the clinical trial HERE.
IMMUNE12 is currently being evaluated by PMB for its potential to revolutionize cancer treatment in the areas of efficacy, safety and delivery. While current cancer treatments can be successful in extending life by several months, they are risky, not curative, and often have debilitating side effects. With its formulation, Immune12 is being evaluated for potential:
